“Advances in the pharmacotherapy of Heart Failure: type 2 sodium-glucose cotransporter Inhibitors (SGLT2) as a therapeutic option” (2023) Research, Society and Development, 12(3), p. e12412340502. doi:10.33448/rsd-v12i3.40502.